Interleukin-1beta and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects

Clin Exp Allergy. 2003 Oct;33(10):1415-8. doi: 10.1046/j.1365-2222.2003.01770.x.

Abstract

Background: Exacerbations of asthma are often associated with rhinovirus (RV)-induced common colds. During experimental RV-infection in healthy subjects, increased levels of the pro-inflammatory mediator IL-1beta and the anti-inflammatory IL-1 receptor antagonist (IL-1ra) have been found in nasal lavage.

Objective: We postulated that the balance between nasal pro- and anti-inflammatory mediator expression is disturbed in asthma, resulting in more extensive inflammation following RV-exposure in asthma.

Methods: We determined IL-1ra, IL-1beta, and IL-8 in nasal lavages (days -2, 3, and 6) of non-asthmatics and asthmatics (with and without pre-treatment with the inhaled steroid budesonide) before and after experimental RV16-infection (days 0 and 1).

Results: Following RV16-infection, a significant increase in IL-8 was observed in the placebo- and budesonide-treated asthmatics (P=0.033 and 0.037, respectively), whereas IL-1beta only increased in the two asthma groups combined (P=0.035). A small, but significant, increase in IL-1ra was only observed in the budesonide-treated asthmatics (P=0.047). At baseline, IL-1ra levels were significantly higher in the non-asthmatics than in the placebo-treated asthmatics (P=0.017).

Conclusion: These results demonstrate differences between non-asthmatic and asthmatic subjects in the basal levels of nasal cytokines and their inhibitors, and in the effect of experimental RV-infection on these levels. The results indicate that RV may enhance inflammation more markedly in asthmatics, and suggest that this may in part be explained by lower IL-1ra levels. In addition, the observation that budesonide-treatment may result in higher nasal IL-1ra levels supports the hypothesis that steroids act in part by increasing the endogenous anti-inflammatory screen.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asthma / complications
  • Asthma / drug therapy
  • Asthma / metabolism*
  • Bronchodilator Agents / therapeutic use
  • Budesonide / therapeutic use
  • Common Cold / complications
  • Common Cold / metabolism*
  • Double-Blind Method
  • Humans
  • Inflammation Mediators / metabolism
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / metabolism*
  • Interleukin-8 / metabolism
  • Nasal Lavage Fluid / chemistry*
  • Rhinovirus*
  • Sialoglycoproteins / metabolism

Substances

  • Bronchodilator Agents
  • IL1RN protein, human
  • Inflammation Mediators
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Interleukin-8
  • Sialoglycoproteins
  • Budesonide